Table II.
Comparison of associated indicators before and after vildagliptin or placebo treatments.
| Indicator | Before treatment (mean ± SD) | After treatment (mean ± SD) | t-value | P-value |
|---|---|---|---|---|
| Vildagliptin group (n=294) | ||||
| Weight, kg | 65.14±10.317 | 65.84±10.454 | 0.066 | 0.935 |
| FBG, mmol/l | 9.22±1.691 | 6.52±0.702 | 6.288 | <0.0001 |
| MPPG, mmol/l | 10.23±1.657 | 8.13±0.635 | 6.040 | <0.0001 |
| HbA1c, % | 8.76±1.718 | 6.65±1.251 | 4.261 | <0.0001 |
| ALT, U/l | 30.44±15.846 | 33.94±11.275 | 2.343 | 0.129 |
| AST, U/l | 22.89±7.676 | 27.23±6.857 | 1.245 | 0.251 |
| CHOL, mmol/l | 4.96±1.009 | 4.50±0.882 | 1.517 | 0.138 |
| TG, mmol/l | 1.93±1.383 | 1.36±0.853 | 1.539 | 0.133 |
| HDL, mmol/l | 1.18±0.331 | 1.15±0.239 | 0.385 | 0.713 |
| LDL, mmol/l | 2.77±0.671 | 2.58±0.731 | 1.267 | 0.214 |
| UREA, mmol/l | 5.58±1.652 | 5.91±2.089 | −0.370 | 0.724 |
| CREA, μmol/l | 57.18±13.367 | 57.21±14.564 | 0.036 | 0.972 |
| Placebo group (n=292) | ||||
| Weight, kg | 63.67±9.794 | 64.69±9.381 | −0.009 | 0.993 |
| FBG, mmol/l | 8.86±1.445 | 8.60±1.274 | 0.573 | 0.572 |
| MPPG, mmol/l | 10.33±1.395 | 9.70±1.348 | 1.539 | 0.136 |
| HbA1c, % | 8.42±1.368 | 8.26±1.180 | 1.061 | 0.296 |
| ALT, U/l | 23.38±9.928 | 26.89±8.065 | −1.198 | 0.249 |
| AST, U/l | 20.67±5.246 | 23.67±4.666 | −1.867 | 0.071 |
| CHOL, mmol/l | 4.53±1.096 | 4.77±0.950 | −0.132 | 0.904 |
| TG, mmol/l | 1.85±1.373 | 1.99±1.327 | −0.099 | 0.932 |
| HDL, mmol/l | 1.08±0.287 | 1.24±0.501 | −1.992 | 0.054 |
| LDL, mmol/l | 2.45±0.836 | 2.67±0.812 | −0.468 | 0.657 |
| UREA, mmol/l | 5.67±1.366 | 5.56±1.419 | 0.922 | 0.363 |
| CREA, μmol/l | 60.57±20.359 | 64.61±21.947 | −0.559 | 0.580 |
SD, standard deviation; FBG, fasting blood glucose; MPPG, mean postprandial glucose; HbA1c, glycated hemoglobin; ALT, alanine aminotransferase; AST, aspartate aminotransferase; CHOL, total cholesterol; TG, total triglycerides; HDL, high density lipoproteins; LDL, low density lipoproteins; UREA, urea; CREA, creatinine.